Overview

« Hoʻi i ka Pipeline

Hoʻohana mākou i ka ʻepekema ʻokiʻoki e hana i nā lāʻau lapaʻau hou e hoʻomaikaʻi ai i ke ola o ka poʻe i loaʻa i ka maʻi kanesa, ka ʻeha intractable a me COVID-19.

Cancer He ʻokoʻa ka genetically, adaptive loa, hoʻololi mau a ʻike ʻole ʻia e ka ʻōnaehana pale. Hoʻokumu ʻia kā mākou hoʻokokoke ʻana i ka lāʻau lapaʻau maʻi maʻi ma ka manaʻoʻiʻo e koi ana nā mea maʻi i kahi multimodal, multipronged approach - e ʻimi ana i kahi hoʻonohonoho hoʻokahi a ʻano like ʻole paha o nā pahuhopu kelepona a me ka hoʻouka ʻana i nā mea ma nā ʻaoʻao he nui - i ka manawa like a i ʻole ka hopena, pinepine a mau ʻole.

ʻO kā mākou hoʻokokoke ʻana i ka hakakā ʻana i ka maʻi maʻi hiki ke hana ʻia e kahi kōpili immuno-oncology (“IO”) kūʻokoʻa, i loaʻa i kahi ʻano nui o nā waiwai hou a synergistic, e like me ka hale waihona puke antibody kanaka holoʻokoʻa (“G-MAB™”) hiki ke hiki. e hoʻohana ʻia iā lākou iho a i hoʻohui ʻia i loko o nā ala e hoʻopaʻa ai i ka maʻi kanesa e like me:

Hoʻohui ʻia kēia mau waiwai e kahi mea hoʻolālā lymphatic hou (Sofusa®) i hoʻolālā ʻia e hoʻopuka i nā antibodies i loko o ka ʻōnaehana lymphatic, kahi i aʻo ʻia ai nā cell immune e hakakā i ka maʻi kanesa. 

Ua hana mākou i nā antibodies kanaka e kūʻē i nā pahuhopu nui i ka mālama ʻana i ka maʻi kanesa, me PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, a me nā pahuhopu ʻē aʻe he nui, aia ma nā pae like ʻole o ka hoʻomohala ʻana. Loaʻa i kā mākou papahana CAR-T ke kahua lapaʻau CD38 CAR T. ʻO nā lāʻau lapaʻau e hui pū ana i nā hoʻokokoke i loko o ka loiloi pae preclinical no ka nui o ka myeloma, ka maʻi maʻi ʻāmāmā, a me nā maʻi maʻi maʻi makua a me nā keiki.

  • ʻO CAR T (Chimeric Antigen Receptor - T Cells) ka lāʻau lapaʻau e hoʻololi i nā T-cell ponoʻī o ka mea maʻi e pepehi i ko lākou ʻōpū.
  • ʻO DAR T (Dimeric Antigen Receptor – T Cells) ka lāʻau lapaʻau e hoʻololi ana i nā pūnaʻi T o ka mea hāʻawi olakino e hoʻoikaika i ka maʻi ʻaʻai o kēlā me kēia maʻi, e ʻae ai i ka mālama ʻana i ka maʻi koko o ka mea maʻi.
  • Antibody-Drug Conjugates (“ADCs”), a
  • Nā polokalamu Virus Oncolytic (Seprehvir™, Seprehvec™)

"ʻO kā mākou waihona kūʻokoʻa o nā waiwai platform IO ʻaʻole i hoʻohālikelike ʻia i ka ʻoihana. Loaʻa iā ia nā mea hoʻopaʻa hoʻopaʻa kino, nā antibodies bispecific, antibody-drug conjugates (ADCs) a me ka chimeric antigen receptor (CAR) a me ka dimeric antigen receptor (DAR) i hoʻokumu ʻia i nā maʻi cellular, a i kēia manawa ua hoʻohui mākou i nā maʻi oncolytic (Seprehvir™, Seprehvec ™). Hōʻike kēlā me kēia waiwai i ka hoʻohiki nui; hui pū mākou manaʻo ua hiki iā lākou ke uhaki i nā pilikia maʻi maʻi paʻakikī loa"

– Kauka Henry Ji, Luna Nui

ʻO kā mākou kūpaʻa e hoʻomaikaʻi i ke ola o nā poʻe maʻi me ka mea i manaʻo ʻia i kēia manawa he ʻeha hiki ke hōʻike ʻia e kā mākou hoʻoikaika mau ʻana e hoʻomohala i kahi mole liʻiliʻi non-opioid mua (TRPV1 agonist), Resiniferatoxin ("RTX").

Hiki i ka Resiniferatoxin ke hoʻololi nui i ke ala i ka mālama ʻana i ka ʻeha ma nā ʻano hōʻailona like ʻole, ma muli o ka ikaika a me ka hopena lōʻihi me ka hoʻokele hoʻokahi akā no nā pōmaikaʻi o kāna profile non-opioid.

Ke hoʻopau nei ʻo RTX i nā hoʻokolohua pre-pivotal i nā hōʻailona kanaka e like me ka osteoarthritis a me ka ʻeha o ke ola maʻi kanesa, me nā haʻawina hoʻopaʻa inoa pivotal i hoʻonohonoho ʻia e hoʻomaka i ka hapalua ʻelua 2020.

Aia ʻo RTX i nā hoʻokolohua koʻikoʻi no ka noi ʻana i nā ʻīlio hoa me ka paʻakikī o ka mālama ʻana i ka ʻeha kuʻe lima. ʻOiai ʻo nā holoholona he ʻāpana o ka ʻohana, ʻo kā mākou ala i ka hoʻomohala ʻana i nā hoʻonā hoʻoponopono ʻehaʻeha i manaʻo ʻia e komo pū me nā ʻano ʻē aʻe a mākou e aloha ai!